Equities research analysts expect that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will post $658.79 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Endo International’s earnings, with the lowest sales estimate coming in at $651.36 million and the highest estimate coming in at $668.22 million. Endo International reported sales of $634.86 million in the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The business is scheduled to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that Endo International will report full-year sales of $2.76 billion for the current financial year, with estimates ranging from $2.74 billion to $2.78 billion. For the next financial year, analysts anticipate that the company will post sales of $2.70 billion, with estimates ranging from $2.55 billion to $2.82 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, August 5th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Endo International had a negative return on equity of 94.51% and a net margin of 2.46%. The firm had revenue of $713.83 million for the quarter, compared to analysts’ expectations of $657.27 million. During the same period in the prior year, the firm posted $0.65 earnings per share.
A number of hedge funds have recently bought and sold shares of ENDP. Geode Capital Management LLC lifted its holdings in Endo International by 15.5% in the first quarter. Geode Capital Management LLC now owns 4,105,987 shares of the company’s stock valued at $30,425,000 after acquiring an additional 549,953 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in Endo International in the first quarter valued at about $3,546,000. LSV Asset Management lifted its holdings in Endo International by 1,928.1% in the second quarter. LSV Asset Management now owns 452,259 shares of the company’s stock valued at $2,116,000 after acquiring an additional 429,959 shares during the period. Alpha Paradigm Partners LLC bought a new position in Endo International in the second quarter valued at about $1,120,000. Finally, Tudor Investment Corp Et Al lifted its holdings in Endo International by 179.8% in the second quarter. Tudor Investment Corp Et Al now owns 355,531 shares of the company’s stock valued at $1,664,000 after acquiring an additional 228,477 shares during the period. 79.73% of the stock is currently owned by institutional investors.
Shares of Endo International stock traded up $0.11 during trading on Friday, hitting $2.83. 8,635,220 shares of the company’s stock traded hands, compared to its average volume of 6,340,223. Endo International has a 1 year low of $1.94 and a 1 year high of $10.89. The stock has a market capitalization of $660.81 million, a P/E ratio of 10.11 and a beta of 1.37. The business has a 50-day simple moving average of $3.50 and a 200-day simple moving average of $5.19.
About Endo International
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.
Featured Article: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.